4//SEC Filing
MICHEL GERARD J 4
Accession 0000899243-23-010009
CIK 0000872912other
Filed
Mar 29, 8:00 PM ET
Accepted
Mar 30, 9:00 AM ET
Size
10.8 KB
Accession
0000899243-23-010009
Insider Transaction Report
Form 4
MICHEL GERARD J
DirectorCHIEF EXECUTIVE OFFICER
Transactions
- Purchase
Common Stock
2023-03-29$4.84/sh+19,646$95,087→ 197,235 total - Purchase
Tranche A Warrants to Purchase Common Stock
2023-03-29$0.13/sh+31,110$3,889→ 31,110 totalExercise: $4.50From: 2023-03-29→ Common Stock (31,110 underlying) - Purchase
Tranche B Warrants to Purchase Common Stock
2023-03-29$0.13/sh+16,666$2,083→ 16,666 totalExercise: $6.00From: 2023-03-29→ Common Stock (16,666 underlying)
Footnotes (4)
- [F1]The common stock and Tranche A and Tranche B Warrants were acquired in the issuer's private placement of common stock and warrants, issued as part of a unit. The per unit purchase price was $5.09, including a purchase price of $4.84 per share of common stock and $0.125 for each of the Tranche A and Tranche B Warrants. Each unit consisted of one share of common stock and an accompanying common stock warrant valued at 140% of the aggregate purchase price (the Tranche A Warrant) and an accompanying common stock warrant valued at 100% of the aggregate purchase price (the Tranche B Warrant).
- [F2]The Tranche A Warrants and Tranche B Warrants are immediately exercisable.
- [F3]The Tranche A Warrants expire the earlier of (i) twenty-one (21) days following the date of the Issuer's public announcement of its receipt of written approval from the U.S. Food and Drug Administration of its New Drug Application for HEPZATO (the "FDA Approval") and (ii) March 31, 2026.
- [F4]The Tranche B Warrants expire the earlier of (i) twenty-one (21) days following the date of the Issuer's public announcement of record at least $10,000,000 in quarterly U.S. revenue from the commercialization of HEPZATO and (ii) March 31, 2026, provided, however, if the FDA Approval occurs on or before February 15, 2024 and the Tranche A Warrants have not been exercised in full on or before March 7, 2024, then the Tranche B Warrants shall automatically expire on March 8, 2024.
Documents
Issuer
DELCATH SYSTEMS, INC.
CIK 0000872912
Entity typeother
Related Parties
1- filerCIK 0001235644
Filing Metadata
- Form type
- 4
- Filed
- Mar 29, 8:00 PM ET
- Accepted
- Mar 30, 9:00 AM ET
- Size
- 10.8 KB